bioCSL

ALK, bioCSL partner for allergy tablets

Wednesday, February 11, 2015

ALK and bioCSL have entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as Grazax in Europe and Grastek in North America), and its adrenaline auto-injector, Jext. ALK will be responsible for product supply and bioCSL will undertake registration and commercialization of the products.

[Read More]